Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stamulumab vs human tetanus immunoglobulin for tetanus prophylaxis in high‑risk severe trauma patients
ChiCTR2600124770Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of stamulumab in Tetanus (2 arms), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoint: Increase in anti-tetanus neutralizing antibody titer from baseline at 12 hours post-dose. Planned start May 2026; status: not yet recruiting.
02
Drugs
stamulumab
03
Conditions
Tetanus
Beyond the preview
Go deeper on ChiCTR2600124770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124770.